Exact Sciences Corp
Avatud
SektorTervishoid
104.93
Ülevaade
Aktsiahinna muutus
24h
Min
104.9
Max
104.96
Sissetulek | -66M -86M |
|---|---|
Müük | 28M 878M |
Aktsiakasum | -0.21 |
Kasumimarginaal | -9.786 |
Töötajad | 7,100 |
EBITDA | -68M -20M |
Soovitused | Neutraalne |
|---|---|
12 kuu keskmine prognoos | +0.09% upside |
Turukapital | 404M 20B |
|---|---|
Eelmine avamishind | 104.93 |
Eelmine sulgemishind | 104.93 |
Tehniline skoor
By Trading Central
Kindlus
Strong Bullish Evidence
Exact Sciences Corp Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Exact Sciences Corp Prognoos
Hinnasiht
By TipRanks
0.09% tõus
12 kuu keskmine prognoos
Keskmine 105 USD 0.09%
Kõrge 105 USD
Madal 105 USD
Põhineb 6 Wall Streeti analüütiku instrumendi Exact Sciences Corp 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
$
Ettevõttest Exact Sciences Corp
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
